Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix-IPV/Hib is a combination vaccine indicated for active immunisation of infants and young children from 2 months of age against five serious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive disease caused by Haemophilus influenzae type b. The vaccine contains purified antigens for each component: diphtheria toxoid, tetanus toxoid, three acellular pertussis antigens (pertussis toxin [PT], filamentous hemagglutinin [FHA], and pertactin), inactivated polio virus types 1–3 (Mahoney, MEF1, Saukett strains), and purified polyribosyl-ribitol-phosphate capsular polysaccharide from Hib covalently bound to tetanus toxoid. The mechanism of action is to stimulate the immune system to produce protective antibodies against these pathogens without causing disease. Developed by GlaxoSmithKline for pediatric use as part of routine childhood immunization schedules[1][2][4].
- Brand names
- Infanrix-IPV/HibInfanrix-IPV+Hib
- Other names
- DTPa-IPV-Hibdiphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed)
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine.